Introduction/Background Estimated ASRs per European standard of endometrial cancer, incidence by sex, cancer site and country, in Europe in 2018 was equal to 22.2 per 100,000 person-years (ASR - Age Standardized Rate).

Methodology The study is based on 199 patients with endometrial cancer and was performed between 2009–2015 at the Pomeranian Medical University. The determinations were made using the ARCHITECT CA 125 II analyzer (Abbott Diagnostics).

Results Statistically significant differences were found between CA125 levels in patients with endometrial endometrioid adenocarcinoma and non-endometrioid endometrial carcinoma (p=0.044). The mean concentration of the CA125 marker was statistically significantly higher in the group of FIGO III, IV and G3 patients compared to the average CA125 concentrations in the FIGO I, II and G1 patients, respectively (p=0.014/p=0.039). We have found significantly higher CA125 concentrations in patients with endometrial cancer with invasion of blood vessels (p=0.022) and in patients with lymph node metastases (p=0.016). We did not find statistically significant differences in mean CA125 concentrations by analyzing lymph vessel invasions and depth infiltration myometrium (p=0.056/p=0.078). In the univariate analysis of the COX regression model, the relationship to disease free time (DSF) shows the cut-off point and the median level CA125 (HR=1.82; p=0.002 and HR=1.76; p=0.033). In the multivariate analysis, the strongest relationship with both the time free from disease and total survival is demonstrated by the CA125 cut-off point (HR=1.45, p=0.026 and HR=1.38, respectively p=0.037).

Conclusion CA125 can be a good prognostic factor, isolating the patients with a higher risk of early recurrences and worse prognostications. Determination of the CA125 marker before surgery may allow better treatment individualization and patients follow-up.

Disclosure Nothing to disclose